These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30146778)

  • 1. Therapeutic potential of A2 adenosine receptor pharmacological regulators in the treatment of cardiovascular diseases, recent progress, and prospective.
    Bahreyni A; Avan A; Shabani M; Ryzhikov M; Fiuji H; Soleimanpour S; Khazaei M; Hassanian SM
    J Cell Physiol; 2019 Feb; 234(2):1295-1299. PubMed ID: 30146778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Many Faces of the A2b Adenosine Receptor in Cardiovascular and Metabolic Diseases.
    Eisenstein A; Patterson S; Ravid K
    J Cell Physiol; 2015 Dec; 230(12):2891-7. PubMed ID: 25975415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands.
    Federico S; Spalluto G
    Expert Opin Ther Pat; 2012 Apr; 22(4):369-90. PubMed ID: 22435652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine receptors and diabetes: Focus on the A(2B) adenosine receptor subtype.
    Merighi S; Borea PA; Gessi S
    Pharmacol Res; 2015 Sep; 99():229-36. PubMed ID: 26142494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenosine A2A receptor as a drug discovery target.
    de Lera Ruiz M; Lim YH; Zheng J
    J Med Chem; 2014 May; 57(9):3623-50. PubMed ID: 24164628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting A2 adenosine receptors in cancer.
    Allard D; Turcotte M; Stagg J
    Immunol Cell Biol; 2017 Apr; 95(4):333-339. PubMed ID: 28174424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of adenosine signaling in sickle cell therapeutics.
    Field JJ; Nathan DG; Linden J
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):287-99. PubMed ID: 24589267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of the adenosine A3 receptor, not the A1 or A2 receptors, promote neurite outgrowth of retinal ganglion cells.
    Nakashima KI; Iwao K; Inoue T; Haga A; Tsutsumi T; Mochita MI; Fujimoto T; Tanihara H
    Exp Eye Res; 2018 May; 170():160-168. PubMed ID: 29486164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine 2A receptor: a crucial neuromodulator with bidirectional effect in neuroinflammation and brain injury.
    Dai SS; Zhou YG
    Rev Neurosci; 2011; 22(2):231-9. PubMed ID: 21476942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential therapeutic relevance of adenosine A2B and A2A receptors in the central nervous system.
    Popoli P; Pepponi R
    CNS Neurol Disord Drug Targets; 2012 Sep; 11(6):664-74. PubMed ID: 22963436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents.
    Preti D; Baraldi PG; Moorman AR; Borea PA; Varani K
    Med Res Rev; 2015 Jul; 35(4):790-848. PubMed ID: 25821194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer.
    Kazemi MH; Raoofi Mohseni S; Hojjat-Farsangi M; Anvari E; Ghalamfarsa G; Mohammadi H; Jadidi-Niaragh F
    J Cell Physiol; 2018 Mar; 233(3):2032-2057. PubMed ID: 28233320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's disease.
    Mori A
    Int Rev Neurobiol; 2014; 119():87-116. PubMed ID: 25175962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activating transcription factor 3 in cardiovascular diseases: a potential therapeutic target.
    Zhou H; Li N; Yuan Y; Jin YG; Guo H; Deng W; Tang QZ
    Basic Res Cardiol; 2018 Aug; 113(5):37. PubMed ID: 30094473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin and cardiovascular diseases: Focus on cellular targets and cascades.
    Pourbagher-Shahri AM; Farkhondeh T; Ashrafizadeh M; Talebi M; Samargahndian S
    Biomed Pharmacother; 2021 Apr; 136():111214. PubMed ID: 33450488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Potentials of A2B Adenosine Receptor Ligands: Current Status and Perspectives.
    Chandrasekaran B; Samarneh S; Jaber AMY; Kassab G; Agrawal N
    Curr Pharm Des; 2019; 25(25):2741-2771. PubMed ID: 31333084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine Receptors Differentially Regulate the Expression of Regulators of G-Protein Signalling (RGS) 2, 3 and 4 in Astrocyte-Like Cells.
    Eusemann TN; Willmroth F; Fiebich B; Biber K; van Calker D
    PLoS One; 2015; 10(8):e0134934. PubMed ID: 26263491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid Receptor and Cardiovascular Disease.
    Buonafine M; Bonnard B; Jaisser F
    Am J Hypertens; 2018 Oct; 31(11):1165-1174. PubMed ID: 30192914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A1 and A2A subtype receptor agonists.
    Schindler CW; Karcz-Kubicha M; Thorndike EB; Müller CE; Tella SR; Ferré S; Goldberg SR
    Br J Pharmacol; 2005 Mar; 144(5):642-50. PubMed ID: 15678095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of neuregulin-1 in cardiovascular disease.
    Mendes-Ferreira P; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C
    Drug Discov Today; 2013 Sep; 18(17-18):836-42. PubMed ID: 23384772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.